

## FY2024 R&D Tax Incentive Loan Funding

---

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (**Rhythm** or the **Company**) advises it has entered into a secured loan facility agreement (Loan) which will provide early access to \$1.15M cash of its forecast ~\$1.5M FY24 R&D Tax Incentive (RDTI Rebate) expected to be received in full by November 2024.

The Loan is secured by and repayable out of the FY24 RDTI Rebate and attracts a fixed 1.33% per month interest rate. It matures on 31 December 2024, however, can be extended by agreement between the lender and Rhythm. This Loan is intended to be used in a bridging period prior to receiving the FY24 RDTI Rebate, along with the amended FY23 RDTI rebate for overseas activities.

Funds received will be used in ongoing operations including the development of the new, multiplex assay version of ColoSTAT<sup>®</sup>, ongoing exploration of previously described new clinical indications and further R&D studies into other cancers, developing and securing partnerships and day-to-day working capital requirements.

- ENDS -

Authorised for release by the Board.

For further information contact us via [investor@rhythmbio.com](mailto:investor@rhythmbio.com):

<b>Dr. David Atkins</b> Chief Executive Officer	<b>Mr. Guy Carisbrooke</b> Financial Controller
--	--

### **About Rhythm Biosciences**

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and Twitter.

### **About ColoSTAT<sup>®</sup>**

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT<sup>®</sup> Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT<sup>®</sup> Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.